Investors purchased shares of Amgen Inc. (NASDAQ:AMGN) on weakness during trading hours on Monday. $134.69 million flowed into the stock on the tick-up and $80.73 million flowed out of the stock on the tick-down, for a money net flow of $53.96 million into the stock. Of all equities tracked, Amgen had the highest net in-flow for the day. Amgen traded down ($0.92) for the day and closed at $160.18

AMGN has been the subject of a number of research analyst reports. Morgan Stanley increased their price objective on shares of Amgen from $193.00 to $195.00 in a research report on Friday, April 8th. Cowen and Company reaffirmed a “buy” rating on shares of Amgen in a research report on Sunday, April 17th. Vetr cut shares of Amgen from a “strong-buy” rating to a “buy” rating and set a $159.22 price objective for the company. in a research report on Monday, March 21st. Royal Bank Of Canada reaffirmed a “buy” rating and set a $190.00 price objective on shares of Amgen in a research report on Wednesday, March 16th. Finally, BMO Capital Markets reaffirmed a “buy” rating and set a $186.00 price objective (up previously from $183.00) on shares of Amgen in a research report on Saturday, April 30th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. Amgen currently has an average rating of “Buy” and an average price target of $182.34.

The firm’s 50 day moving average is $154.11 and its 200 day moving average is $152.65. The stock has a market cap of $120.33 billion and a price-to-earnings ratio of 16.95.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 28th. The medical research company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.60 by $0.30. During the same period in the prior year, the company posted $2.48 earnings per share. The firm had revenue of $5.53 billion for the quarter, compared to analysts’ expectations of $5.32 billion. Amgen’s quarterly revenue was up 9.8% compared to the same quarter last year. On average, analysts expect that Amgen Inc. will post $11.18 EPS for the current year.

In other Amgen news, EVP Madhavan Balachandran sold 30,000 shares of the company’s stock in a transaction dated Wednesday, May 4th. The shares were sold at an average price of $154.12, for a total transaction of $4,623,600.00. Following the completion of the sale, the executive vice president now directly owns 23,097 shares of the company’s stock, valued at $3,559,709.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Sean E. Harper sold 21,875 shares of the company’s stock in a transaction dated Friday, April 29th. The shares were sold at an average price of $157.99, for a total transaction of $3,456,031.25. Following the sale, the executive vice president now directly owns 42,248 shares of the company’s stock, valued at $6,674,761.52. The disclosure for this sale can be found here.

A number of hedge funds have recently bought and sold shares of the stock. World Asset Management Inc raised its stake in Amgen by 2.3% in the fourth quarter. World Asset Management Inc now owns 84,098 shares of the medical research company’s stock worth $13,651,000 after buying an additional 1,912 shares in the last quarter. Bar Harbor Trust Services raised its stake in Amgen by 0.4% in the fourth quarter. Bar Harbor Trust Services now owns 40,275 shares of the medical research company’s stock worth $6,538,000 after buying an additional 155 shares in the last quarter. Becker Capital Management Inc. raised its stake in Amgen by 9.9% in the fourth quarter. Becker Capital Management Inc. now owns 290,288 shares of the medical research company’s stock worth $47,122,000 after buying an additional 26,154 shares in the last quarter. Twin Capital Management Inc. raised its stake in Amgen by 11.3% in the fourth quarter. Twin Capital Management Inc. now owns 46,985 shares of the medical research company’s stock worth $7,627,000 after buying an additional 4,780 shares in the last quarter. Finally, Henderson Group PLC raised its stake in Amgen by 78.5% in the fourth quarter. Henderson Group PLC now owns 172,301 shares of the medical research company’s stock worth $27,966,000 after buying an additional 75,783 shares in the last quarter.

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.